-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Innovation announced that its holding subsidiary Jushi Biotech recently launched a phase IB/II clinical trial of SYS6090 injection combined with advanced or metastatic colorectal cancer. This product is a class 1 recombinant all-human anti-PD-1 fusion of IL-15 protein. Currently, the recruitment and screening of participants is being actively promoted.

Zhitongcaijing·08/03/2026 08:09:08
Listen to the news
CSPC Innovation announced that its holding subsidiary Jushi Biotech recently launched a phase IB/II clinical trial of SYS6090 injection combined with advanced or metastatic colorectal cancer. This product is a class 1 recombinant all-human anti-PD-1 fusion of IL-15 protein. Currently, the recruitment and screening of participants is being actively promoted.